RespireRx Pharmaceuticals Inc (RSPI)

[tonyvanw]

<That doesn't preclude COR providing enough detail to lay this to rest, without providing their competitors with proprietary information. Something along the lines of "the FDA was unconvinced by our explanation of histological anomalies as post-mortem artifact of the fixation process" vs "the FDA determined that CX-717 induced histological changes that could not be accounted for as artifacts of the fixation process".>

I seem to recollect, though I don't know where or when, that the company position was "the FDA was unconvinced by our explanation of histological anomalies as post-mortem artifact of the fixation process"

I doubt that you will get anything more from either the company or the FDA. There is nothing to be gained for the company with respect to the FDA and what else could be said to shareholders.